Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms

Pharmiweb.com RSS Feed Pharmiweb.com RSS Feeds

Pharmiweb.com RSS Feed PharmiWeb Candidate Blog

Pharmiweb.com RSS Feed PharmiWeb Client Blog

Advertising

Press Release

Emblem Corp. By-Law Amendment and Investor Relations Services Update


Posted on: 25 Aug 17

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES.

PARIS, Ontario, Aug. 25, 2017 (GLOBE NEWSWIRE) -- Emblem Corp. (TSXV:EMC) (“Emblem” or the "Company") amended and restated By-Law No. 1 of the Company to provide  that  the quorum requirement for a meeting of shareholders of the Company shall be two (2) persons, present in person, each being a shareholder or representative duly authorized in accordance with the Canada Business Corporations Act entitled to vote at the meeting or a duly appointed proxy for a shareholder so entitled and holding or representing, in the aggregate, not less than five percent (5%) of the votes entitled to be cast at the meeting of shareholders.

In addition to the foregoing, the Company has entered into an amended investor relations and capital markets advisory services agreement (the "Agreement") with Spinnaker Capital Markets Inc. (“Spinnaker”) pursuant to which Spinnaker will provide capital markets and investor relations advisory services to Emblem until April 30, 2020.

Pursuant to the Agreement and as disclosed in the Company's press release dated April 17, 2017, the Company has issued an aggregate of 200,000 incentive stock options with an exercise price of $2.60 per share and will pay Spinnaker a monthly fee of $10,000 plus applicable taxes. The Agreement is subject to the acceptance of the TSX Venture Exchange.

About Emblem

Emblem is licensed under the Access to Cannabis for Medical Purposes Regulations (the “ACMPR”) to cultivate and sell medical marihuana. Emblem carries out its principal activities producing marihuana from its facilities in Paris, Ontario pursuant to the provisions of the ACMPR and the Controlled Drugs and Substances Act (Canada) and its regulations.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

This news release contains certain forward-looking statements and forward-looking information (collectively referred to herein as "forward-looking statements") within the meaning of applicable Canadian securities laws. All statements other than statements of present or historical fact are forward-looking statements. Forward-looking statements are often, but not always, identified by the use of words such as "anticipate", "achieve", "could", "believe", "plan", "intend", "objective", "continuous", "ongoing", "estimate", "outlook", "expect", "may", "will", "project", "should" or similar words, including negatives thereof, suggesting future outcomes.

Management of the Company believes the expectations reflected in such forward-looking statements are reasonable as of the date hereof but no assurance can be given that these expectations will prove to be correct and such forward-looking statements should not be unduly relied upon. Any forward-looking statements are made as of the date hereof and, except as required by law, the Company assumes no obligation to publicly update or revise such statements to reflect new information, subsequent or otherwise.

GlobeNewswire
globenewswire.com

Last updated on: 28/08/2017

Advertising
Share | | |
Site Map | Privacy & Security | Cookies | Terms and Conditions

PharmiWeb.com is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on PharmiWeb.com is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.